Tradestie Institutional Equity Comparison Engine
CRBN vs BMED โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRBN Overall Edge
CRBN Captures Institutional Edge (1โ1 Pillars ยท 2โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to iShares MSCI ACWI Low Carbon Target ETF (CRBN) driven by superior Options & Structure while BMED counters with relative strength in Momentum & Technical. Fundamentally, CRBN trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus BMED at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, CRBN sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against BMED sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CRBN N/M vs BMED N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner
BMED
1Y +7.7% vs +26.0% ยท 52W Pos 67% vs 85%
Options & Structure Winner
CRBN
UNCLASSIFIED (50th %ile IV) vs UNCLASSIFIED (100th %ile IV)
CRBN
NYSE Arca
iShares MSCI ACWI Low Carbon Target ETF
Institutional Equity
$246.70
-1.96% 1D
Market Cap
N/A
1M Return
-2.75%
1Y Return
+7.72%
Forward P/E
N/M
Unified AI Score
60.1 / 100
BUY
Tech 75.0
Fund 60.0
Flow 50.0
Mom 50.0
BMED
NYSE Arca
iShares Health Innovation Active ETF
Institutional Equity
$35.85
-1.28% 1D
Market Cap
N/A
1M Return
+3.76%
1Y Return
+26.0%
Forward P/E
N/M
Unified AI Score
51.8 / 100
HOLD
Tech 44.0
Fund 44.0
Flow 50.0
Mom 41.6
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CRBN +7.72%
BMED +26.0%
Spread: +15.67 pp (BMED Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CRBN TTM Op. Margin: N/A
BMED TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRBN vs BMED. Trailing 12-month operating profitability (CRBN N/A vs BMED N/A) and valuation multiples (CRBN N/M vs BMED N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRBN | BMED | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | N/A | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | N/A | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | N/A | N/A | Higher Margin | Tie |
| Net Profit Margin Profitability | N/A | N/A | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | N/A | N/A | Higher ROE | Tie |
| 52-Week Range Position Momentum | 67% ($215โ$262) | 85% ($27โ$37) | Stronger Trend | BMED |
| Beta / 30D Volatility Risk Regime | 1.07ฮฒ ยท 22% Vol | 0.61ฮฒ ยท 24% Vol | Lower Realized Risk | CRBN |
| Unified Institutional Score Composite Signal | 60.1 / 100 (BUY) | 51.8 / 100 (HOLD) | Higher Composite | CRBN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CRBN vs BMED Buy Guide
CRBN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
50th %ile
IV Regime
Balanced (25thโ60th %ile)
BMED
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CRBN nor BMED registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.